Personalis (NASDAQ:PSNL) Price Target Raised to $12.00

Personalis (NASDAQ:PSNL) had its price target increased by Guggenheim from $6.00 to $12.00 in a research report sent to investors on Tuesday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Several other equities research analysts also recently weighed in on PSNL. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. BTIG Research increased their price objective on shares of Personalis from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday. Needham & Company LLC boosted their target price on shares of Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Lake Street Capital restated a “buy” rating and set a $11.00 price target on shares of Personalis in a research note on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Personalis presently has an average rating of “Moderate Buy” and an average price target of $10.29.

Personalis Trading Down 5.1%

Shares of PSNL stock opened at $7.60 on Tuesday. Personalis has a 12-month low of $2.83 and a 12-month high of $10.95. The business’s fifty day simple moving average is $7.59 and its 200-day simple moving average is $6.18. The company has a market cap of $674.88 million, a PE ratio of -8.64 and a beta of 1.92.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The firm had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts forecast that Personalis will post -1.4 earnings per share for the current year.

Insider Transactions at Personalis

In other Personalis news, CEO Christopher M. Hall sold 29,612 shares of Personalis stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the sale, the chief executive officer directly owned 148,486 shares in the company, valued at approximately $1,334,889.14. The trade was a 16.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 3.80% of the company’s stock.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC raised its holdings in shares of Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares during the last quarter. AIGH Capital Management LLC grew its position in Personalis by 4.5% during the 1st quarter. AIGH Capital Management LLC now owns 3,968,948 shares of the company’s stock worth $13,931,000 after purchasing an additional 169,884 shares during the period. Aberdeen Group plc raised its stake in shares of Personalis by 35.7% during the 3rd quarter. Aberdeen Group plc now owns 2,387,947 shares of the company’s stock valued at $15,569,000 after buying an additional 628,450 shares during the last quarter. Kennedy Capital Management LLC raised its stake in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after buying an additional 1,281,695 shares during the last quarter. Finally, Blue Water Life Science Advisors LP lifted its holdings in shares of Personalis by 42.6% in the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock valued at $10,997,000 after buying an additional 500,900 shares during the period. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.